GLUE Key Statistics, Chart & Performance
The current stock price of GLUE is 17.64 USD. In the past month the price increased by 10.11%. In the past year, price increased by 149.86%.
GLUE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About GLUE
Company Profile
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 147 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Company Info
MONTE ROSA THERAPEUTICS INC
321 Harrison Avenue, Suite 900
Boston MASSACHUSETTS US
CEO: Markus Warmuth
Employees: 142
Phone: 16179492643
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you describe the business of MONTE ROSA THERAPEUTICS INC?
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 147 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Can you provide the latest stock price for MONTE ROSA THERAPEUTICS INC?
The current stock price of GLUE is 17.64 USD. The price increased by 7.04% in the last trading session.
Does GLUE stock pay dividends?
GLUE does not pay a dividend.
What is the ChartMill rating of MONTE ROSA THERAPEUTICS INC stock?
GLUE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the market cap for MONTE ROSA THERAPEUTICS INC?
MONTE ROSA THERAPEUTICS INC (GLUE) has a market capitalization of 1.15B USD. This makes GLUE a Small Cap stock.
What is the next earnings date for GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) will report earnings on 2026-03-18, after the market close.
Can you provide the ownership details for GLUE stock?
You can find the ownership structure of MONTE ROSA THERAPEUTICS INC (GLUE) on the Ownership tab.
GLUE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GLUE. When comparing the yearly performance of all stocks, GLUE is one of the better performing stocks in the market, outperforming 98.58% of all stocks.
GLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GLUE. While GLUE has a great health rating, its profitability is only average at the moment.
GLUE Financial Highlights
Over the last trailing twelve months GLUE reported a non-GAAP Earnings per Share(EPS) of 0.31. The EPS increased by 116.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.54% | ||
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| Debt/Equity | 0 |
GLUE Forecast & Estimates
15 analysts have analysed GLUE and the average price target is 17.78 USD. This implies a price increase of 0.78% is expected in the next year compared to the current price of 17.64.
For the next year, analysts expect an EPS growth of 71.45% and a revenue growth 424.57% for GLUE